Dal-OUTCOMES Trial: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) Created page with "__NOTOC__ {{High density lipoprotein}} {{CMG}} ==Overview== * Research studies on dalcetrapib were stopped due to lack of clinically and statistically meaningful efficacy..." |
Rim Halaby (talk | contribs) No edit summary |
||
| Line 12: | Line 12: | ||
[[Category:Lipopedia]] | [[Category:Lipopedia]] | ||
[[Category:HDL]] | [[Category:HDL]] | ||
[[Category:Clinical trials]] | |||
Revision as of 23:34, 17 September 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
Dal-OUTCOMES Trial On the Web |
|
American Roentgen Ray Society Images of Dal-OUTCOMES Trial |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
- Research studies on dalcetrapib were stopped due to lack of clinically and statistically meaningful efficacy of the drug on interim analysis.[1]
- The Dal-Outcomes study[2] assessed dalcetrapib at various dose ranges. This study showed a significant rise in HDL levels, but there was no significant difference between the drug and the placebo group.
References
- ↑ Lüscher TF, Taddei S, Kaski JC; et al. (2012). "Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial". European Heart Journal. 33 (7): 857–65. doi:10.1093/eurheartj/ehs019. PMC 3345558. PMID 22345126. Unknown parameter
|month=ignored (help) - ↑ Schwartz GG, Olsson AG, Abt M; et al. (2012). "Effects of dalcetrapib in patients with a recent acute coronary syndrome". The New England Journal of Medicine. 367 (22): 2089–99. doi:10.1056/NEJMoa1206797. PMID 23126252. Unknown parameter
|month=ignored (help)